Pacific Biosciences：情况只会变得更糟 (NASDAQ:PACB)
· seekingalpha.com
Pacific Biosciences 报告的第二季度营收为 3901 万美元，低于预期，并下调了 2026 年的营收指引，低于市场共识。阅读为什么 PACB 股票评级为“卖出”。
After the bell on Wednesday, we received second quarter results from Pacific Biosciences ( PACB ). The sequencing solutions company has been one of the most dis...